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Protocol
AbstrACt
Introduction Dementia is one of the greatest health 
challenges the world will face in the coming decades, as it 
is one of the principal causes of disability and dependency 
among older people. Economic modelling is used widely 
across many health conditions to inform decisions on 
health and social care policy and practice. The aim of 
this literature review is to systematically identify, review 
and critically evaluate existing health economics models 
in dementia. We included the full spectrum of dementia, 
including Alzheimer’s disease (AD), from preclinical 
stages through to severe dementia and end of life. This 
review forms part of the Real world Outcomes across the 
Alzheimer’s Disease spectrum for better care: multimodal 
data Access Platform (ROADMAP) project.
Methods and analysis Electronic searches were 
conducted in Medical Literature Analysis and Retrieval 
System Online, Excerpta Medica dataBASE, Economic 
Literature Database, NHS Economic Evaluation Database, 
Cochrane Central Register of Controlled Trials, Cost-
Effectiveness Analysis Registry, Research Papers 
in Economics, Database of Abstracts of Reviews of 
Effectiveness, Science Citation Index, Turning Research 
Into Practice and Open Grey for studies published between 
January 2000 and the end of June 2017. Two reviewers 
will independently assess each study against predefined 
eligibility criteria. A third reviewer will resolve any 
disagreement. Data will be extracted using a predefined 
data extraction form following best practice. Study quality 
will be assessed using the Phillips checklist for decision 
analytic modelling. A narrative synthesis will be used.
Ethics and dissemination The results will be made 
available in a scientific peer-reviewed journal paper, will be 
presented at relevant conferences and will also be made 
available through the ROADMAP project.
PrOsPErO registration number CRD42017073874.
IntrOduCtIOn
Dementia is a progressive neurodegenerative 
disease that encompasses cognitive and func-
tional impairment and behavioural symp-
toms.1 People living with dementia may have 
difficulty with language, memory, perception, 
behaviour and activities of daily living. Impair-
ments increase as the disease progresses,1 and 
strengths and limitations of this study
 ► This systematic literature review of published eco-
nomic models of dementia and Alzheimer’s disease 
(AD) is broad in terms of disease stages since the 
searches are being conducted across the full spec-
trum of dementia, including AD, from preclinical 
stages through to severe dementia and end of life.
 ► The searches cover a wide range of databases using 
detailed search strategies and include studies from 
any Organisation for Economic Co-operation and 
Development (OECD) country published in English 
language between January 2000 and June 2017.
 ► The review will be reported in accordance with the 
Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses statement and will use the 
Phillips checklist for decision analytic modelling 
to assess the quality of the models reported in the 
studies.
 ► We are excluding conference abstracts, commen-
taries and studies in languages other than English.
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there is no curative treatment. Caring for a person with 
dementia may also considerably affect the quality of life 
and health of caregivers who experience increased rates 
of depression and financial difficulties.2 
An estimated 47 million people are believed to be living 
with dementia worldwide, and—as a result of demographic 
shifts towards an ageing society and increased survival of 
people with dementia—that number is expected to rise 
to around 131 million by 2050.3 Dementia exerts a consid-
erable toll on people living with dementia and their care-
givers, its impact reaches health and social care systems 
and the wider society1; the global cost of dementia was 
estimated to be US$818 billion in 2015 and is projected to 
rise to US$2 trillion by 2030.4
Alzheimer’s disease (AD) is the most common cause 
of dementia. AD is a spectrum; the earliest stage of 
the disease is mild cognitive impairment (MCI) where 
patients experience a reduction in their cognitive abilities 
beyond the expected cognitive decline for their age and 
education.1 The symptoms may be subtle, and MCI may 
go unrecognised for some time.1 While MCI may be due 
to the early stages of AD,5–8 MCI can result from other 
clinical conditions including depression and medication 
side effects, which—unlike AD—may be reversible. The 
need for early detection and intervention in MCI is there-
fore crucial.1
Economic models can examine progression of AD from 
early stages such as MCI to severe dementia, in order to 
quantify the impact of AD across the spectrum of clinical 
severity. Robust economic models guide policymakers in 
deciding how best to allocate scarce public funds. While 
economic models have been used extensively for other 
health conditions—such as stroke, diabetes, obesity and 
cardiovascular diseases9—such modelling has been rela-
tively less used for AD.10 However, as the number of people 
living with dementia increases, high-quality economic 
models will be required to provide the tools for govern-
ments and other decision makers to implement cost-ef-
fective solutions to make the best use of scarce resources.
Some reviews have discussed the use of economic 
modelling in AD,10–17 mainly to compare alternative inter-
ventions rather than to identify methodological issues 
and data gaps affecting the economic evaluation.10–14 
Most of the existing systematic literature reviews focused 
their searches on a limited number of databases (mainly 
PubMed, Embase and EconLit). In 2011, Green et al10 
conducted a systematic literature review on methods of 
modelling disease progression in AD.
This systematic literature review updates and builds on 
this existing work. It aims systematically to review existing 
economic models of dementia—all forms of dementia, 
including but not limited to AD—across the full spec-
trum of disease severity, from preclinical stages through 
to severe dementia and end of life,18 and including 
models of the full range of interventions except primary 
prevention.
This review will inform further stages of the Real 
world Outcomes across the Alzheimer’s Disease 
spectrum for better care: multimodal data Access 
Platform (ROADMAP) project, in particular the devel-
opment of a new proof-of-concept model to evaluate the 
cost-effectiveness of interventions for the full spectrum of 
dementia, including AD, from preclinical stages through 
to severe dementia and end of life.
In this context, the review aims to meet three specific 
objectives:
1. To systematically identify previous economic model-
ling studies across the full spectrum of dementia, in-
cluding AD, from preclinical stages through to severe 
dementia and end of life care.
2. To describe the key features of those models in terms 
of their aim, structure, coverage, data sources and out-
puts.
3. To assess the quality of existing models and de-
scribe their main strengths and weaknesses following 
best practice guidelines for the evaluation of mod-
el-based economic evaluations.
MEthOds And AnAlysIs
Protocol and registration
This systematic literature review protocol is reported 
in accordance with the Preferred Reporting Items for 
Systematic review and Meta-Analysis Protocols (online 
supplementary file 1).19 The protocol has been registered 
with the PROSPERO international prospective register of 
systematic reviews (CRD42017073874). The results of this 
review will be reported following the Preferred Reporting 
Items for Systematic Review and Meta-Analysis (PRISMA) 
statement.20–22 Any amendments to this protocol will be 
reported and published.
study selection criteria
Participants
This review focuses on all adults in all care settings in the 
full spectrum of dementia, including AD, from preclin-
ical stages through to severe dementia and end of life. 
Although AD is the core of this review, we cover all forms 
of dementia and include dementia among our search 
terms.
Study design
The review includes studies reporting existing economic 
models across any part of the dementia or AD spectrum 
(from preclinical stages through to severe dementia and 
end of life).
The following study designs will be considered for 
inclusion and further consideration: cost–utility analysis, 
cost-effectiveness analysis, cost–benefit analysis, cost-min-
imisation analysis, cost analysis, cost-consequences anal-
ysis, economic evaluation, health technology appraisal 
and treatment pathway study.
We will exclude editorials, case studies, phase I and 
phase II clinical trials, newspaper articles, book sections, 
patient and expert opinion or commentary, social media 
and papers describing adaptations of existing economic 
models. Papers that fail to meet any one of the above 
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eligibility criteria will be excluded from the review. The 
number of excluded studies (including reasons for their 
exclusion) will be recorded.
Outcomes
The outcome measures of interest include:
 ► Model type and structure.
 ► Markers/measure used to model disease progression.
 ► Types of clinical/disease pathways.
 ► Data used to structure and parameterise the model.
 ► Summary/synthesis of challenges, limitations and 
data gaps for developing an economic model for 
preclinical, MCI and AD/dementia.
Intervention
All types of AD or dementia interventions (both symp-
tomatic and disease modifying) will be included.
Context
Models developed in any OECD country will be included 
as long as the paper is written in English.
search strategy
Electronic databases
The following electronic databases were searched for 
papers published between 1 January 2000 and 27 June 
2017: Medical Literature Analysis and Retrieval System 
Online (Ovid MEDLINE); Excerpta Medica data-
BASE (Ovid Embase); Economic Literature Database 
(EconLit); NHS Economic Evaluation Database; Cochrane 
Central Register of Controlled Trials; Cost-Effectiveness Anal-
ysis Registry; Research Papers in Economics; Database 
of Abstracts of Reviews of Effectiveness; Science Citation 
Index; Turning Research Into Practice; and Open Grey 
(online supplementary file 2).
The search terms include (but not limited):
 ► AD, dementia and mild cognitive impairment.
 ► Cost-effectiveness analysis, cost–utility analysis, cost 
analysis, economic models, Markov chains, simula-
tion and pharmacoeconomics.
The search strategies are designed such that to be 
selected for review of title and abstract papers needed to 
contain a term from each of these two categories. A copy 
of the search strategies is available on the online supple-
mentary file 2.
Manual searching
The reference lists of studies included in the review are 
being hand-searched to identify any additional literature.
Study selection
The electronic reference management tool EndNote 
X7 by Thomson Reuters will be used in order to export 
and manage the references. Duplicates will be removed 
by one reviewer (MKa), and all the remaining titles and 
abstracts identified through the searches will be reviewed 
against the predefined eligibility criteria by two reviewers 
(MKa and AP) in order to determine if there is a need 
for a further full-text review. The relevance of each study 
will be assessed according to the inclusion and exclusion 
criteria. For those studies that appear to meet the inclu-
sion criteria, or in cases where a decision cannot be safely 
made based on the title/abstract only, a full text will be 
retrieved for the assessment. Studies that do not fulfil the 
inclusion criteria will be excluded. Disagreements are will 
be resolved by a third reviewer (RW).
The full process will be presented in a flow chart and in 
detail according to PRISMA guidelines.20
data extraction
Two reviewers (AP and MKa) will extract the data from 
the included studies (online supplementary file 3). 
They will each independently check the data extraction 
forms for accuracy and completeness. Any disagree-
ments will be noted and resolved by a third reviewer 
(RW).
The following information will be extracted:
 ► Study details: title, author, publication details, 
language of the study, aim of the study, countries of 
the study, funding of the study and study funding 
source.
 ► Study design: objective of the study, purpose of the 
modelling, types of modelling study (ie, review of 
models), type of model, model input data, model 
output, source of data incorporated into the model, 
model perspective and model time horizon.
 ► The intervention evaluated.
 ► Setting: community setting, institutional setting, 
primary care, secondary care, tertiary care and mixed 
setting.
 ► Participant information: type of participant, number 
of participants and demographic information.
 ► Disease-specific information: type of dementia, level 
of severity and disease progression measurement.
 ► Outcomes: outcomes modelled and costs (and cost 
types).
 ► Approach to model validation and evidence of valida-
tion performance.
 ► Key findings.
 ► Author’s comments on strengths and weaknesses of 
the model and potential gaps in available data.
risk of bias (quality) assessment
The quality of the model is the core of our review. Thus, 
the quality of identified models will be assessed from the 
perspective of best current practice. The ‘Philips check-
list’,23 24 as recommended by the Cochrane Handbook for 
Systematic Reviews of Interventions,25 will be used to assess 
the quality of the models reported in the studies included 
in the review. Two researchers will independently review 
and assess the models. The Phillips checklist was devel-
oped for assessing the quality of decision-analytic models 
in health technology assessment. It was designed to be 
used both by analysts developing models and by reviewers 
assessing such models. It comprises nine points on the 
structure of the model, five on the data used in the model 
and two on model validation.
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strategy for data synthesis
A narrative synthesis will be used for the present study.
Ethics and dissemination plans
The included studies will be reviewed to ensure ethical 
considerations were taken into account. The results will 
be published in the form of a publication in a peer-re-
viewed journal. In addition, the results will be presented 
at conferences and will be published in the ROADMAP 
project’s official website (http:// roadmap- alzheimer. 
org/).
Patient and public involvement
Alzheimer Europe, representing patient and carer asso-
ciations across Europe, is a partner in the ROADMAP 
consortium and has been fully involved from the begin-
ning in the design and progress of the overall project, 
including this systematic literature review.
dIsCussIOn
Economic models are useful to inform policy deci-
sions by providing evidence on the cost-effectiveness 
of current and new interventions. The aim of this 
systematic literature review is to systematically identify 
and review the existing economic modelling method-
ologies across the full spectrum of dementia, including 
AD, from preclinical stages through to severe dementia 
and end of life.18 The focus will be on the models, their 
structure and the information and assumptions used 
to parameterise them and not on the interventions 
per se. We will consider modelling of both symptom-
atic and disease-modifying interventions.18 The way in 
which disease progression is represented in economic 
models will also be covered.18 This systematic litera-
ture review will inform the design and development 
of future economic modelling across the full spectrum 
of dementia, including AD, from preclinical stages 
through to severe dementia and end of life and will 
identify gaps in data and research.
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